Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant pembrolizumab for high-risk melanoma without detectable metastasis
2024-517840-68-00Phase 2Authorised
- Sponsor
- UZ Brussel
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in cutaneous melanoma (CM), sponsored by UZ Brussel. Primary endpoint: Negative sentinel node procedure rate. Planned start Mar 2025; status: authorised.
02
Drugs
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2024-517840-68-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517840-68-00.